Phase II study of Irinotecan, TS-1 and Bevacizumab as second-line treatment in patients with advanced colorectal cancer (KMOG 0708)
收藏NIAID Data Ecosystem2026-03-06 收录
官方服务：
资源简介：
Interventions: TS-1+CPT-11+Bevacizumab Primary outcome(s): Response Rate Study Design: Single arm Non-randomized
创建时间：
2008-01-15
